Cases
Representative Matters: Capital Markets, Private Equity
Venture Capital Transactions
Advised a Florida-based designer, importer, distributor
licensor of men's apparel in connection with its $150 million public bond offering, $150 million universal shelf public offering
$40 million secondary public offering.
Counseled a privately-held drug delivery technology
generic pharmaceutical company in connection with its $25 million
$10 million private offerings of partnership interests.
Assisted a foreign private issuer with a public follow-on offering of $43 million of ordinary shares.
Represented a publicly-traded biopharmaceutical company in registered direct public offerings of more than $20 million for common stock
warrants to institutional investors.
Represented the shareholders of Ideal Protein, a Quebec-based corporation with significant U.S. operations, in the sale of a majority interest to funds advised by Apax Partners LLP, a global private equity firm.
Closed multiple technology-based growth company transactions, including venture capital financings, strategic alliances, licenses, development
supply arrangements totaling over $500 million in the last five years.
Represented a publicly-traded life sciences company in several public
private securities offerings totaling more than $100 million.
Advised a privately-held software development company in connection with several venture capital financings in excess of $50 million.
Counseled a privately-held orthopedic medical device manufacturer in connection with private financings in excess of $60 million.
Represented a privately-held biometric fingerprint sensor designer
manufacturer in connection with private financings in excess of $80 million.
Represented an electronic health records/patient care management company in connection with a $500,000 investment by an angel group based in Orl
o, Florida.
Mergers
Acquisitions
Represented a leading national provider of workers' compensation industry specialized cost containment services in acquiring a health care service provider that facilitates the measurement
tracking of health care quality
efficiency
Advised a privately-held, Taiwan-based medical device company in connection with a multi-million dollar acquisition of a medical device product line owned by a public company based in the United States.
Represented a publicly-traded life sciences company in connection with the purchase of assets owned by a Canadian corporation.
Counseled publicly-traded financial services company in connection with a reverse triangular merger which resulted in the realization of significant wealth by the majority shareholders.
Represented a publicly-traded media company in connection with its merger with another public company, valued at $38.5 million
Represented a publicly-traded biopharmaceutical company in connection with the acquisition of a Phase 3 clinical trial-ready drug c
idate
all related assets, including the intellectual property
rights to develop
commercialize the drug product.
Represented a publicly-traded internet-based weight-loss company in connection with its merger with a provider of interactive private-label nutrition, fitness
wellness programs.
SEC Compliance
Corporate Governance
Regularly advise public companies in connection with the preparation
filing of periodic reports required by the Securities Exchange Act of 1934.
Advised publicly-traded company in connection with implementation of shareholders' rights plan to discourage certain types of transactions involving an actual or potential change of control of the company.
Represented several public
private companies in the establishment
use of equity incentive plans
a wide range of equity incentives for executives, employees, directors
consultants.
Advised several public companies in corporate governance matters under the Sarbanes-Oxley Act of 2002
related regulations.
